BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month

BURLINGTON, Mass. and Jerusalem, Israel, May 02, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced the launch of #DontMissAnotherMoment, a social media campaign dedicated to raising awareness and conversation around of mental health. The campaign, which runs throughout May, encourages people to share photos of their most precious moments in life to affirm their hope that those moments will endure even in the face of mental illness.

During May, Mental Health Awareness Month, BrainsWay donate up to $10,000 – with $5 per share, $2 by social comment, and $1 by social like – to Mental Health America (MHA) in support of their ongoing efforts to promote mental health for all.

“Sixty million people in United States face the daily reality of living with mental illness and every American is touched by their friends and family,” said Christopher von JakoPh.D., President and CEO of BrainsWay. “Mental Health Awareness Month reminds us of what people with mental illness miss, including some of life’s most memorable moments. Our #DontMissAnotherMoment campaign supports people with mental illness by encouraging their use of social media to show how joy can be found – while raising money for an amazing charity.

The campaign continues to show BrainsWay’s commitment to raising awareness about mental health, as well as modern treatment options, including Deep TMS™. BrainsWay’s Deep TMS treatment is FDA cleared for patients with depression, including depression with comorbid anxiety symptoms (anxious depression), obsessive-compulsive disorder (OCD), and tobacco addiction. Through a padded helmet, electromagnetic pulses are delivered to target deep brain structures to treat the patient’s symptoms. The treatment is non-invasive, drug-free, and patients can resume normal activities, such as driving, immediately after the session.

To participate in the campaign, share photos of life moments you wouldn’t want to miss and include the hashtag, #DontMissAnotherMoment. You can also share and comment on BrainsWay social media posts on Facebook, Twitter and/or Instagram.

On BrainsWay
BrainsWay is a world leader in advanced non-invasive neurostimulation treatments for mental health disorders. The company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-approved indications supported by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxiety depression), obsessive-compulsive disorder, and tobacco addiction. The company is committed to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological and addictive disorders are ongoing. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and wide access to Deep TMS. For the latest news and information on BrainsWayplease visit

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be prefaced by the words “intends”, “may”, “will”, “expects”, “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements and their implications are based on the current expectations of the Company’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . In addition, the pilot data presented here, including outcomes/results, patient safety information, and adverse event data, remain subject to further analysis and may be subject to additional changes. Some results as expressed here may be subject to further analysis, modification and/or statistical penalties. In addition, historical results or the conclusions of scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted in the same way light of further research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: insufficient financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in initiating and/or completing planned clinical studies and trials; failure to obtain regulatory approvals within the Company’s timelines, or at all; failure to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or failure to develop necessary improvements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in applicable laws and rules and regulations; adverse market perception and acceptance of Deep TMS technology; insufficiency or delays in reimbursement by third-party payers, including insurance companies and Medicare; inability to market Deep TMS, including internationally, by the Company or through third-party distributors; development of products by competitors; failure to develop and introduce new technologies, products and applications on a timely basis; the continuation and/or worsening of the global supply chain crisis and its impact on the Company’s ability to source components, meet customer demand, fulfill orders, maintain price levels and meeting the Company’s service needs; and the effect of the COVID-19 global health pandemic on our business and the continued uncertainty and market impact related thereto.

Any forward-looking statements in this press release speak only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities laws. More detailed information on the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the documents filed by the Company with the US Securities and Exchange Commission, including the company’s annual report on Form 20-F. Investors and security holders are urged to read these materials free of charge on the SEC’s website at

contacts:Scott AregladoSVP and CFO
[email protected]

Investors:Bob YedidLifeSci Advisors
[email protected]

Media Contact:Will Johnson(201) 465-8019
[email protected]

main logo

Source: BrainsWay

2022 GlobeNewswire, Inc., source Press Releases

Comments are closed.